Skip to main content
Premium Trial:

Request an Annual Quote

Inproteo Subsidiary Prosolia Licenses Electrospray Technology to Thermo Electron

NEW YORK, Sept. 7 (GenomeWeb News) - Prosolia, a subsidiary of Inproteo, today announced that it has agreed to license its ElectroSonicSpray Ionization technology to Thermo Electron. Financial terms of the deal were not disclosed.

 

The ESSI technology is a proprietary ionization technique that enables ionization of large molecules such as protein and protein complexes, while retaining their conformation and function, Prosolia said.

 

Ian Jardine, Thermo Electron's chief technology officer, said in an official statement that Thermo would likely commercially implement the technology in early 2005 to complement the current technique of electrospray ionization and MALDI for analyzing large biological molecules.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.